As of late May 2026, the Merck stock price is trading around $122.41, navigating a complex macroeconomic landscape and major shifts in the pharmaceutical sector. For value investors, income seekers, and growth-oriented biotech analysts, Merck & Co., Inc. (NYSE: MRK) represents one of the most intriguing puzzles on Wall Street. On one hand, the company is powered by Keytruda, the world's top-selling oncology therapeutic. On the other hand, Merck faces a looming patent cliff in late 2028, leading many to ask: is MRK a secure buy, or does its reliance on a single blockbuster present too much risk?

By diving deep into Merck's recent fourth-quarter and full-year 2025 earnings, its projected 2026 guidance, policy shifts, and breakthrough clinical data ahead of the 2026 ASCO Annual Meeting, this analysis provides an authoritative playbook for investors evaluating the Merck stock price today.

Merck (NYSE: MRK) Current Stock Price and Market Standing

Currently trading at $122.41, Merck possesses a massive market capitalization of over $270 billion, establishing it as a cornerstone of the global healthcare sector. Historically, MRK has been favored for its low beta, defensive characteristics, and robust capital return program. Over the last year, the Merck stock price has traded in a steady channel, establishing a solid support floor around $109 and testing resistance near $146.

At its current valuation, Merck trades at a forward price-to-earnings (P/E) ratio of approximately 18.4x. This is highly aligned with the large-cap pharmaceutical industry average, which currently hovers around 18.5x. However, this multiple is slightly elevated compared to Merck's historical five-year mean of 12.51x. The premium reflects Wall Street's growing optimism regarding Merck's strategic pivot toward a diversified, post-Keytruda revenue model.

From an income perspective, Merck remains a premier dividend stock. With an annualized dividend payout that yields over 2.7%, the stock is highly attractive to defensive income-focused portfolios. This yield is underpinned by strong free cash flow generation and a highly disciplined capital allocation framework that balances dividend growth with aggressive business development (BD) and research and development (R&D) investments.

Deciphering the Financials: FY 2025 Earnings & 2026 Guidance

To understand the fundamental direction of the Merck stock price, we must analyze its recent financial performance. In February 2026, Merck reported its fourth-quarter and full-year 2025 financial results, beating analyst expectations on several key metrics:

• Worldwide Sales: Full-year 2025 sales reached $65.0 billion, representing 1% nominal growth (2% excluding foreign exchange headwinds). Fourth-quarter sales came in at $16.4 billion, a 5% year-over-year increase.
• Earnings Per Share (EPS): Full-year 2025 GAAP EPS was reported at $7.28, while non-GAAP EPS stood at $8.98. For Q4 2025, Merck posted non-GAAP EPS of $2.04, slightly ahead of the consensus Wall Street estimate of $2.03.
• Operating Efficiency: The company maintained a stellar 38% operating margin, a reflection of its highly profitable biologics mix and optimized global supply chain.

However, the real talking point that shook the market was Merck's full-year 2026 guidance. Management guided worldwide sales to be between $65.5 billion and $67.0 billion. Meanwhile, it estimated non-GAAP EPS to be between $5.00 and $5.15.

To the untrained eye, a drop from $8.98 in 2025 to a guided $5.15 in 2026 looks alarming. But smart investors recognize the nuance: this guidance reflects a massive, one-time charge of approximately $3.65 per share related to the acquisition of Cidara Therapeutics, alongside other business development transactions. When adjusting for this one-time accounting impact, Merck's underlying core operating earnings remain highly stable, showing solid top- and bottom-line expansion. This highlights why looking past raw, surface-level stock screeners is essential when analyzing the Merck stock price.

The Keytruda Conundrum and the 2028 Patent Cliff

No discussion of Merck's valuation is complete without examining Keytruda (pembrolizumab). In 2025, the oncology juggernaut generated a staggering $31.7 billion in sales, growing 7% year-over-year. Keytruda alone accounts for roughly 48% of Merck's total pharmaceutical revenues, illustrating an extraordinary level of concentration.

The primary risk hanging over the Merck stock price is the looming loss of exclusivity (LOE) for Keytruda's primary compound patent in late 2028. Once biosimilars enter the market, Merck faces a sharp decline in Keytruda sales.

However, CEO Robert Davis and his leadership team are executing a multi-pronged strategy to neutralize this threat:

1. Keytruda Qlex (Subcutaneous Formulation): Merck has successfully launched its subcutaneous formulation, Keytruda Qlex, which recorded initial sales of $40 million in Q4 2025. By transitioning patients from the intravenous (IV) version to a highly convenient subcutaneous injection, Merck can extend the patent runway and protect its market share.
2. Additional Indications and Combination Regimens: Merck continues to expand Keytruda's clinical utility. Just recently, in May 2026, the European Medicines Agency's CHMP adopted a positive opinion recommending Keytruda in combination with Padcev as a perioperative treatment for adults with cisplatin-ineligible resectable muscle-invasive bladder cancer.
3. Defending Secondary Patents: While the main patent expires in 2028, Merck holds secondary patents that extend through late 2029. Management has expressed immense confidence in their ability to legally defend these patents, which could push the steep revenue drop-off out by an extra year, providing a crucial financial buffer.

The $70 Billion Growth Runway: Merck's Post-Keytruda Portfolio

To replace the eventual revenue decline of Keytruda, Merck has built a massive pipeline and executed strategic acquisitions. Management recently announced that they foresee major new sales opportunities delivering over $70 billion in potential annual revenue by the mid-2030s—more than double Keytruda's projected peak sales of $35 billion in 2028.

This $70 billion growth runway is anchored by several key pillars:

1. Winrevair (Sotatercept)

Launched in 2024 for the treatment of pulmonary arterial hypertension (PAH), Winrevair has exhibited phenomenal launch momentum, pulling in $1.4 billion in sales in 2025. As Merck expands Winrevair into earlier stages of PAH and secures broader global regulatory approvals, this biologic is expected to become a multi-billion-dollar blockbuster, providing immediate top-line diversification.

2. Next-Gen Oncology and Antibody-Drug Conjugates (ADCs)

Rather than relying solely on immunotherapy, Merck is investing heavily in ADCs—biomedical 'guided missiles' that deliver chemotherapy directly to cancer cells.

• Sacituzumab Tirumotecan (sac-TMT): Licensed from Sichuan Kelun-Biotech, this TROP2-directed ADC is shaping up to be a monumental pipeline success. Ahead of the 2026 ASCO Annual Meeting, Phase 3 OptiTROP-Lung05 trial results revealed that the sac-TMT plus Keytruda combination reduced the risk of disease progression or death by a staggering 65% compared to Keytruda alone in first-line advanced non-small cell lung cancer (NSCLC). This trial demonstrates Merck's ability to build synergistic oncology platforms that survive long after Keytruda's base patent expires.
• Daiichi Sankyo Collaboration: Merck's multi-billion-dollar alliance with Daiichi Sankyo targets three clinical-stage ADC candidates, establishing a formidable oncology moat.

3. Cardiometabolic and Immunology Expansion

Merck's $10.8 billion acquisition of Prometheus Biosciences brought in highly promising candidates for inflammatory bowel disease (IBD). Additionally, Merck is advancing MK-0616, an oral PCSK9 inhibitor for high cholesterol, currently in late-stage Phase 3 clinical trials. If successful, an oral daily pill for cholesterol could disrupt a multi-billion-dollar market currently dominated by injectables.

4. Vaccines and Animal Health

While Gardasil (HPV vaccine) faced temporary headwinds in China during 2025, leading to a decline in international sales, the franchise remains a foundational asset with a global market that continues to expand. Furthermore, Merck's Animal Health division is an understated jewel, generating $6.4 billion in sales in 2025 (8% growth) and providing highly predictable, non-cyclical cash flows.

Policy Context: Drug Affordability and Domestic Investment

Evaluating the Merck stock price in 2026 also requires understanding the changing regulatory and political landscape. In December 2025, Merck reached a landmark agreement with the U.S. government regarding drug pricing and affordability.

Under this agreement, Merck committed to over $70 billion in domestic investment, bolstering its manufacturing capacity, securing tariff and supply chain stability, and expanding direct-to-patient access for key therapeutics (such as its diabetes portfolio) at lower prices. While this price restructuring initially compressed margins on legacy drugs, it neutralized severe regulatory threats from drug price negotiation frameworks. By aligning with the administration's goals, Merck secured a highly predictable operational framework in the U.S., a major positive for long-term stock stability.

Wall Street's Verdict: Is Merck a Buy, Sell, or Hold in 2026?

Wall Street analysts are highly optimistic about Merck & Co. In late May 2026, the consensus rating among the 29 major analysts covering MRK is a Strong Buy (8.3 out of 10), with 19 Buy ratings, 10 Hold ratings, and zero Sell ratings.

The consensus 12-month price target for Merck sits around $135.00, representing an approximate 10.3% upside from its current price of $122.41. When factoring in the dividend, investors are looking at a projected double-digit annualized return over the next 12 to 18 months. Some of the most recent analyst actions from major investment banks include:

• UBS: Maintained a Buy rating and raised its price target from $130 to $145.
• Wells Fargo: Maintained an Overweight rating with a price target of $145.
• JP Morgan: Maintained a Buy rating and increased its target to $135.
• Citigroup: Reinstated coverage with a Buy rating and a $125 target.

The Bull Case

• De-risked Pipeline: Winrevair's rapid uptake and sac-TMT's outstanding ASCO 2026 data prove that Merck can replace Keytruda's revenues.
• Excellent Valuation: At 18.4x forward earnings (excluding the one-time Cidara charge), MRK is reasonably valued relative to its blue-chip peers.
• Rock-Solid Income: A reliable, growing dividend yield over 2.7% provides a strong safety net for conservative investors.

The Bear Case

• Patent Cliff Volatility: Despite pipeline progress, any clinical setbacks or regulatory delays for next-gen assets could spark near-term volatility in the Merck stock price.
• Gardasil Recovery in China: Merck must show that its vaccine segment can recover from the temporary distributor issues faced in late 2025.

Frequently Asked Questions (FAQ)

What is the current Merck stock price?

As of May 22, 2026, the Merck stock price closed at $122.41 per share.

What is the ticker symbol for Merck & Co.?

Merck trades on the New York Stock Exchange (NYSE) under the ticker symbol MRK.

Does Merck pay a dividend?

Yes. Merck is highly regarded for its stable dividend program. It currently offers an annualized dividend yield of over 2.7%, supported by strong operating cash flows.

Why is Merck's guided EPS for 2026 lower than its 2025 earnings?

Merck's guided 2026 non-GAAP EPS ($5.00 to $5.15) is lower than its 2025 non-GAAP EPS ($8.98) due to a one-time charge of approximately $3.65 per share associated with the acquisition of Cidara Therapeutics. This is an accounting charge rather than a decline in core business profitability.

When does the Keytruda patent expire?

Keytruda's primary compound patent in the United States is scheduled to expire in late 2028. However, Merck holds secondary patents extending into late 2029 that it plans to legally defend, which could delay the entry of biosimilars.

Conclusion

The Merck stock price at $122.41 offers an attractive entry point for investors who appreciate long-term value and strategic execution. While the Keytruda patent cliff of 2028 is a real obstacle, Merck's aggressive pivot toward a $70 billion diversified pipeline—validated by Winrevair's commercial success and breakthrough ASCO 2026 clinical data for sac-TMT—demonstrates that the company is fully prepared for its next chapter. Backed by solid Wall Street analyst consensus, a highly attractive dividend, and robust financials, MRK remains a cornerstone asset for any diversified portfolio seeking a balance of yield and long-term capital appreciation.